Regeneron (REGN) Tops Q1 EPS by $1.45
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Regeneron Reports First Quarter 2022 Financial and Operating Results
May 4, 2022 6:30 AM EDTTARRYTOWN, N.Y., May 4, 2022 /PRNewswire/ --
First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 25%First quarter 2022 EYLEA® U.S. net sales increased 13% to $1.52 billion versus first quarter 2021First quarter 2022 Dupixent® global net sales(c)(recorded by Sanofi) increased 43% to $1.81 billion versus first quarter 2021First quarter 2022 GAAP diluted EPS of $8.61; non-GAAP diluted EPS(a) of $11.49Dupixent approved in EU for children aged 611 years with severe asthma; FDA priority review... More